DC responses Part 1

Speakers: Diana Gonzalez, CBM RD . Samia Moussa, Pfizer Value Measure Tool

Samia Moussa: Health measure value to.

Samia Moussa: Okay, we know that resource who will be increasing limited and the population getting older and older. So measure the value of the private, the products delivered to the patient and establish agreements based on just value delivered. For sure, we put fighter in a very advantaged position in the future, required in corporations.

Samia Moussa: You have higher defender to measure the value of our products during the project implementation from value pasted agreements. The idea here is to develop a fighter to to measure value in health. With just two, you have an opportunity to have more agility in approval process since you spend a lot of time in discussions with legal compliance that a private team just to should bring us more simplicity since you're going to have only 12 from, from value baited agreement fighter projects. But also you have an opportunity to customize this to consider each disease, each journey, each drugs and also you have an opportunity to scale from different regions. Since you have only one fighter to in value basic agreement.

Samia Moussa: This idea is really something relevant and bring value to our business because you need to implement value basted agreement. You need to measure, learn and improve the next agreements if you have a fighter too, uh, to measure these agreements for sure, you're gonna have an opportunity to improve this process, Okay.

Samia Moussa: three years ago we implemented the innovative agreements, error in Brazil and you had an opportunity to implement different kinds of agreements as capitation from antibiotic subscription from and I vibrancy risk sharing agreement and also affordability projects.

Diana Gonzalez: This is general european in one click, a digital transformation partnership with their parties to increase access and affordability of genotropin in Colombia.

Diana Gonzalez: 1st 1, our project is focused on parents that have the economic resources or pay these training for their Children. So we expect to impact 200 patients with growth disorders and get a revenue of $300,000 in the following three years. Second, there is a reality and with the pandemic pages are more connected than ever to e commerce solutions and getting used to too fast option when the time is definitely priceless. So with this project we have Two points are challenges identify according to the patient journey. 1st 1 is really is related with a cloud cash flow. So there are lack savings and competitive price to leverage out of pocket solution. And second, the time to treatment, there is a delay in receiving the treatment after medical problems, christian based in cash flow for the health care system and the device delivery and training in how to use our product after the payment. So we didn't know what the solution we want to solve the current access and affordability challenges, establishing a partnership with the Columbia's large, it's online e commerce platform to enable online purchasing and including an aliens with a big wholesaler who are capable of manage all the logistics for a co change project and training in the device used that sometimes is not released

Diana Gonzalez: We can say that Colombia's health care system is universal because it covers around 98% of the population. However, it faces access and affordability challenges, especially for budget constraints. This affordability of solution, it's totally aligned with the Ministry of Health Vision, which aims to enhance patient access in a sustainable way, taking in consideration the budget constraints in our system is focused as well and improve the title treatment, and how to between the patients and how to use the product to have more patients other into those therapists.

Diana Gonzalez: We want to build a different business approach for genotropin and other products in Colombia, where patients can easily buy it in a more affordable price, get the device for administration and learning how to use the product just by one click in the platform. Additionally, this is an opportunity to lead the conversation of the benefits of going home with penetrations vision ist.

Diana Gonzalez: Despite the 25 years under commercialization, in a highly competitive market and with a reduction rating diagnosis due to COVID, I can say that this year, at the beginning of the year genotropin became the leader. We became the number one grow horror in our country. We have right now, 91% of the market share and we are the only emerging market when you're not dropping. Actually, this was in part due to a commercial agreement that we got with the second biggest asian mo mm, showing a holistic support of genotropin beyond the price. And when the demo actually the size of switching, um 300 patients from our biggest competitor to generate dropping up there, for example, of excellence and equity invite